Zomedica Pharmaceuticals Corp. (ZOM.V) Stock Forecast, Price & News

-0.02 (-6.56 %)
(As of 02/5/2020)
Today's Range
50-Day Range
52-Week Range
Volume4,800 shs
Average Volume2,858 shs
Market CapitalizationC$36.73 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ZOM News and Ratings via Email

Sign-up to receive the latest news and ratings for Zomedica Pharmaceuticals Corp. (ZOM.V) and its competitors with MarketBeat's FREE daily newsletter.

About Zomedica Pharmaceuticals Corp. (ZOM.V)

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.64 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) Frequently Asked Questions

What stocks does MarketBeat like better than Zomedica Pharmaceuticals Corp. (ZOM.V)?

Wall Street analysts have given Zomedica Pharmaceuticals Corp. (ZOM.V) a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Zomedica Pharmaceuticals Corp. (ZOM.V) wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Zomedica Pharmaceuticals Corp. (ZOM.V)'s key executives?

Zomedica Pharmaceuticals Corp. (ZOM.V)'s management team includes the following people:
  • Mr. Gerald L. Solensky Jr., Chairman, Pres & CEO (Age 45)
  • Mr. Shameze Rampertab B.Sc. MBA, CA, CPA, CFO, Corp. Sec. & Director (Age 52)
  • Dr. Stephanie Morley D.V.M., DVM, COO & VP of Product Devel. (Age 44)
  • Mr. Michael Schilk, VP of Sales
  • Mr. David Eaton, VP of Marketing

Who are some of Zomedica Pharmaceuticals Corp. (ZOM.V)'s key competitors?

What other stocks do shareholders of Zomedica Pharmaceuticals Corp. (ZOM.V) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zomedica Pharmaceuticals Corp. (ZOM.V) investors own include Heat Biologics (HTBX), Biocept (BIOC), Remark (MARK), Onconova Therapeutics (ONTX), Vislink Technologies (VISL), Genius Brands International (GNUS), Ritter Pharmaceuticals (RTTR), T2 Biosystems (TTOO), Guardion Health Sciences (GHSI) and MicroVision (MVIS).

What is Zomedica Pharmaceuticals Corp. (ZOM.V)'s stock symbol?

Zomedica Pharmaceuticals Corp. (ZOM.V) trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ZOM."

How do I buy shares of Zomedica Pharmaceuticals Corp. (ZOM.V)?

Shares of ZOM and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Zomedica Pharmaceuticals Corp. (ZOM.V)'s stock price today?

One share of ZOM stock can currently be purchased for approximately C$0.29.

How much money does Zomedica Pharmaceuticals Corp. (ZOM.V) make?

Zomedica Pharmaceuticals Corp. (ZOM.V) has a market capitalization of C$36.73 million.

How many employees does Zomedica Pharmaceuticals Corp. (ZOM.V) have?

Zomedica Pharmaceuticals Corp. (ZOM.V) employs 27 workers across the globe.

What is Zomedica Pharmaceuticals Corp. (ZOM.V)'s official website?

The official website for Zomedica Pharmaceuticals Corp. (ZOM.V) is

How can I contact Zomedica Pharmaceuticals Corp. (ZOM.V)?

The company can be reached via phone at 734-369-2555.

This page was last updated on 7/27/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.